SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Alterity Therapeutics Limited (PRNAF) .
Criteria proven by this page:
- VALUE (0/100, Fail) — the composite valuation score falls below the 60/100 threshold required to pass.
Overall SharesGrow Score: 46/100 with 2/7 criteria passed.
SharesGrow 7-Criteria Score
✓
HEALTH
100/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — PRNAF
Valuation Multiples
P/E (TTM)0.0
Forward P/EN/A
PEG RatioN/A
Forward PEGN/A
P/B Ratio0.00
P/S Ratio1.29
EV/EBITDA0.0
Per Share Data
EPS (TTM)$0.00
Book Value / Share$0.00
Revenue / Share$0.00
FCF / Share$0.00
Yields & Fair Value
Earnings YieldN/A
Dividend Yield0.00%
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2016 |
$-0.01 |
$142.66K |
$-7.73M |
-5418.3% |
| 2017 |
$-0.01 |
$132.4K |
$-7.54M |
-5696.6% |
| 2018 |
$-0.02 |
$201.17K |
$-8.27M |
-4108.8% |
| 2019 |
$-0.02 |
$4.95M |
$-12.34M |
-249.2% |
| 2020 |
$-0.02 |
$0.00 |
$-13.46M |
- |
| 2021 |
$-0.01 |
$4.34M |
$-15.31M |
-352.8% |
| 2022 |
$-0.01 |
$5.12M |
$-12.85M |
-250.7% |
| 2023 |
$-0.01 |
$3.92M |
$-13.81M |
-352.5% |
| 2024 |
$-0.01 |
$4.02M |
$-19.12M |
-475.8% |
| 2025 |
$0.00 |
$5.44M |
$-12.15M |
-223.4% |
